Ena Respiratory

ENA Respiratory is a clinical-stage pharmaceutical company developing INNA-051, a topical broad-spectrum antiviral immunomodulator for the prevention of respiratory viral infections and their complications in high-risk populations, including the elderly and patients with pre-existing lung conditions such as chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis, as well as infants, the elderly, and immunocompromised patients.